Terns Pharmaceuticals
TERN
Performance
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing a portfolio of small-molecule therapeutics to address serious diseases, with an emphasis on oncology and metabolic conditions such as obesity. The company conducts its research and development activities to advance drug candidates through clinical trials with the aim of delivering targeted cancer therapies and metabolic disease treatments. While the site highlights its headquarters and leadership, it emphasizes a global outlook in oncology and metabolic programs.
Recent News
Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes
PharmaShots Quarterly Outlook: The Forces Reshaping Biopharma in Q1 2026
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
Merck to Acquire Terns Pharmaceuticals for $6.7 B, Accelerating M&A Ahead of Keytruda Patent Expiry
Top Biotech Deals in March 2026
Top 20 Most Innovative Healthcare Companies in 2026, Per Fast Company
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
Oil Prices Fall Even With Ceasefire Plan Uncertainty
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update